Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 6Iodine-131 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3Trastuzumab 2Sorafenib 2Radiotherapy 2trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1omipalisib 1gallium Ga 68 dotatate 1cediranib 1cabozantinib 1aldesleukin 1aflibercept 1Vorinostat 1Triiodothyronine 1Thyrotropin Alfa 1Tamoxifen 1Sunitinib 1Specimen Handling 1Rosiglitazone 1Ritonavir 1Radiofrequency Ablation 1Pharmacogenomic Testing 1Nivolumab 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid Cancer, Papillary × Rosiglitazone × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡